Tuesday, January 16, 2018 -- Lab studies show promise for a clinical trial aimed at improving current immune therapies
Tuesday, January 16, 2018 -- Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma.
Tuesday, January 16, 2018 -- Purpose: New targets are required for the control of advanced metastatic disease. We investigated the use of cadherin RGD motifs, which activate the α2β1integrin pathway, as targets for the development of therapeutic monoclonal antibodies (mAb). Experimental Design: Cadherin 17 (CDH17) fragments and peptides were prepared and used for immunization and antibody development. Antibodies were tested for inhibition of β1 integrin and cell adhesion, proliferation, and invasion assays using cell lines from different cancer types (colorectal, pancreatic, melanoma, and breast cancer). Effects of the mAbs on cell signaling were determined by Western blot analysis. Nude mice were used for survival analysis after treatment with RGD-specific mAbs and metastasis development. Results: Antibodies against full-length CDH17 failed to block the binding to
Wednesday, January 17, 2018 -- Continuation of treatment beyond progression in the product labelling of these immunotherapies has not been recommended because the clinical benefit remains to be proven. Treatment beyond progression with anti-PD-1 antibody therapy might be appropriate for selected patients with unresectable or metastatic melanoma, identified by specific criteria at the time of progression, based on the potential for late responses in the setting of the known toxicity profile.
Tuesday, January 16, 2018 -- UCLA study findings revealed two-thirds of desmoplastic melanoma patients responded positively when immunotherapy treatment was administered. Details of the probe published in Nature outlined the evaluation of 60 people with advanced desmoplastic melanoma who received anti-PD-1 or anti-PD-L1 therapies over … Read More » The post Immunotherapy effective versus desmoplastic melanoma appeared first on Life Science Daily.
Wednesday, January 17, 2018 -- Higher percentage of PD-L1-positive cells in the tumor parenchyma of desmoplastic melanomas
Monday, January 15, 2018 -- Biofrontera has filed for a Nasdaq IPO. The German company is seeking $22 million (€18 million) to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer and other dermatological conditions.
Thursday, January 18, 2018 -- A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology.
Thursday, January 18, 2018 -- Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.